BPC-157 tested as AChE inhibitor in vitro

A May 2026 paper in the International Journal of Molecular Sciences reports that BPC-157, along with two newly designed hybrid peptides called CIARA-1 and CIARA-2, can inhibit acetylcholinesterase (AChE) in a test-tube assay^[1]. AChE is the enzyme that breaks down acetylcholine, a neurotransmitter involved in memory and learning. Blocking it is the mechanism behind the oldest class of approved Alzheimer's drugs, including donepezil, rivastigmine, and galantamine^[2].

The finding is early-stage and entirely in vitro. No animal models, no cell-culture work, and no human data are reported. But it opens a line of inquiry that connects BPC-157 research to a well-established therapeutic target in neurodegeneration.

What the researchers found

Jelinska, Jozwiak, Szeleszczuk, and colleagues at institutions in Poland used enzyme kinetics assays and molecular modelling to measure how strongly BPC-157 and the two hybrid peptides bind to AChE and block its activity^[1]. All three compounds showed competitive inhibition, meaning they compete with acetylcholine for the enzyme's active site rather than binding elsewhere on the protein.

CIARA-1 was the most potent of the three, with an inhibition constant (Ki) of 0.24 mM and a half-maximal inhibitory concentration (IC50) of 2.52 mM. CIARA-2 followed at Ki = 0.29 mM and IC50 = 2.73 mM. BPC-157 itself was the weakest inhibitor of the group, with Ki = 0.48 mM and IC50 = 2.80 mM^[1]. The fact that both hybrid peptides outperformed the parent compound suggests the structural modifications introduced by the researchers improved binding affinity to the enzyme's active site.

To put those numbers in perspective: the approved cholinesterase inhibitors donepezil and galantamine operate at effective concentrations roughly a thousand-fold lower than what these peptides required^[2]. The authors acknowledge this gap explicitly. They describe the peptides as "a promising scaffold for further optimization" rather than as drug candidates ready for preclinical or clinical testing. That phrasing is appropriate given the data presented.

Why this matters for BPC-157 research

Most of the existing BPC-157 literature focuses on wound healing, gut mucosal protection, and musculoskeletal repair in rodent models. A potential interaction with cholinergic signalling is a different direction entirely. The cholinergic system plays a role not only in Alzheimer's disease but also in gut motility, inflammation, and muscle function, all areas where BPC-157 has shown effects in animal experiments.

Whether AChE inhibition explains any of those observed effects, or is simply an incidental binding interaction with no physiological consequence at achievable tissue concentrations, is an open question. The study does not address it. Answering it would require measuring peptide concentrations at the target site in a living organism and correlating those concentrations with changes in acetylcholine levels.

It is also worth comparing the evidence base here with that of approved peptide-based drugs. Semaglutide, for example, went through extensive Phase 2 and Phase 3 programmes involving tens of thousands of patients before regulators approved it. BPC-157 has no published controlled human trial for any indication. The distance between a test-tube enzyme assay and an approved therapy is measured in years of animal testing, toxicology, pharmacokinetics, and randomised clinical trials.

Regulatory status of BPC-157

BPC-157 remains unapproved by every medicines regulator we track. The U.S. FDA considers it an unapproved drug, and the agency has stated there is no legal basis for compounding pharmacies to use it^[3]. The World Anti-Doping Agency (WADA) prohibits BPC-157 under category S0, which covers non-approved substances^[4]. In Europe, it has no marketing authorisation from the EMA or any national agency. It circulates as a grey-market research chemical, primarily through online vendors selling it labelled "for research use only."

The U.S. Department of Defense's Operation Supplement Safety programme specifically warns service members against using BPC-157 in any form, whether injected, taken orally, or applied nasally^[3]. For the full per-country breakdown, see the BPC-157 regulation section on this site.

What the study did not do

The paper tested enzyme inhibition in an isolated biochemical assay. It did not test whether the peptides cross the blood-brain barrier, a requirement for any centrally acting cholinesterase inhibitor. It did not assess whether the peptides remain stable in blood plasma long enough to reach the brain at meaningful concentrations. It did not include any cell-culture experiments to see whether the inhibition affects neuronal signalling. And it did not test any of the compounds in an animal model of cognitive decline.

The hybrid peptides CIARA-1 and CIARA-2 are newly described in this paper, and no prior literature on them exists. Their safety profile, metabolic fate, immunogenicity, and off-target effects are entirely unknown. Even the parent peptide BPC-157, despite a larger body of rodent literature, lacks published human pharmacokinetic data.

The bottom line

This is a proof-of-concept laboratory study showing that BPC-157 and two structural variants can inhibit AChE in vitro, but at potencies far below those of existing approved drugs. It is interesting as basic science, particularly for researchers exploring whether peptide scaffolds can be engineered into enzyme inhibitors. It does not change the practical status of BPC-157, which remains an unapproved, grey-market peptide with no controlled human evidence for any indication.

Readers encountering marketing claims that frame this paper as evidence that BPC-157 "treats" or "prevents" Alzheimer's disease should treat those claims with skepticism. The data do not support that interpretation.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making any decisions about treatment.